Earnings ·
Apyx Medical Corporation reported second quarter 2026 financial results for the period ended June 30, 2026
APYXApyx Medical Corp
Apyx Medical Corporation reported second quarter 2026 financial results for the period ended June 30, 2026. Total revenue increased 22% to $13.9 million from $11.4 million in the prior year, driven by a 28% growth in the Surgical Aesthetics segment to $12.4 million. The company initiated limited commercial shipments of its reusable power liposuction handpiece for the AYON platform in June 2026 following expanded FDA clearance. Net loss attributable to stockholders narrowed to $3.2 million, or $0.07 per share, compared to a $3.8 million loss in the previous year. Adjusted EBITDA improved significantly, with a loss of $0.7 million versus $2.0 million previously. The company reaffirmed its full-year 2026 revenue guidance of $59.0 million to $60.0 million and reported cash and cash equivalents of $27.6 million as of June 30, 2026. Apyx Medical Corporation operates in the surgical aesthetics industry, developing and marketing medical devices such as Renuvion and the AYON Body Contouring System.